The role of extracellular vesicles as biomarkers in colorectal cancer
- 78 Downloads
We read with interest the paper by Nikolaou et al. comparing the diagnostic ability of blood markers in colorectal cancer (CRC) . They described and discussed different diagnostic blood markers in depth. However, we think that an important biomarker with great potential was missed and, although still under evaluation, should be at least cited: extracellular vesicles (EVs). EVs are bound vesicles which are released in the extracellular space from cells in both physiological and pathological conditions, and play a key role in cell-to-cell communication. EVs include two different types of vesicles classified by their size: exosomes and microvesicles. EVs contain specific proteins, lipids, ribonucleic acid (RNA), microRNA and deoxyribonucleic acid (DNA) molecules (Fig. 1) . The term “liquid biopsy” generally refers to the use of circulating (cell-free) tumor DNA or circulating tumor cells as non-invasive biomarkers for the early diagnosis, prognosis, monitoring of clinical...
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
This letter is not reporting any clinical series involving patients. So that, the approval of the Ethical Committee has been not required
For this type of study formal consent is not required.
- 4.Yoshioka Y, Kosaka N, Konishi Y, Ohta H, Okamoto H, Sonoda H, Nonaka R, Yamamoto H, Ishii H, Mori M, Furuta K, Nakajima T, Hayashi H, Sugisaki H, Higashimoto H, Kato T, Takeshita F, Ochiya T (2014) Ultra-sensitive liquid biopsy of circulating extracellular vesicles using ExoScreen. Nat Commun 5:3591CrossRefGoogle Scholar
- 6.Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H (2017) High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients. Ann Oncol 28:741–747PubMedPubMedCentralGoogle Scholar